SCHEMBL5162783

SCHEMBL5162783

COCCCc1cc(Br)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DYRK1A Q13627 1/20 0.36
NOS2 P35228 3/20 0.36
NOS3 P29474 2/20 0.36
NOS1 P29475 2/20 0.36
KDM4E B2RXH2 6/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 3/20 0.33
SREBF2 Q12772 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
CNR2 P34972 1/20 0.33
KCNH2 Q12809 1/20 0.33
LNPEP Q9UIQ6 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1048028 0.95 KDM4E (0.37) SMN1; SMN2HTTHSD17B10DYRK1ANOS2
SCHEMBL22637134 0.89 DYRK1A (0.38) SMN1; SMN2HTTHSD17B10DYRK1ANOS2
SCHEMBL13605796 0.83 HTT (0.43) SMN1; SMN2HTTHSD17B10NOS2KDM4E
SCHEMBL5549765 0.81 HTT (0.41) SMN1; SMN2HTTHSD17B10DYRK1ANOS2
SCHEMBL10264193 0.80 KDM4E (0.42) SMN1; SMN2NOS2NOS3NOS1KDM4E
SCHEMBL27644599 0.79 KCNH2 (0.44) SMN1; SMN2HTTKDM4ELMNANPC1
SCHEMBL12434098 0.78 KDM4E (0.37) SMN1; SMN2HSD17B10DYRK1ANOS2NOS3
SCHEMBL23815855 0.77 KCNH2 (0.47) SMN1; SMN2HSD17B10KDM4ELMNANPC1
SCHEMBL31590556 0.77 KCNH2 (0.47) SMN1; SMN2HSD17B10KDM4ELMNANPC1
SCHEMBL1051073 0.77 DYRK1A (0.37) SMN1; SMN2HTTHSD17B10DYRK1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066604-A1 Diaminoalcohols as therapeutic compounds SPEEDEL EXPERIMENTA AG (CH) 2007-03-22 US disclosed
EP-1764098-A1 Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV Speedel Experimenta AG (CH) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066604-A1 Diaminoalcohols as therapeutic compounds CTSD, FURIN, CTSL SMN1; SMN2 2531/4885HTT 1199/4885HSD17B10 3063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.